New Long-Read Genetic Test Enables Faster and More Comprehensive Diagnosis of Rare Diseases
November 18, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Nesina,Incresync,kazano,oseni
Synonyms :
Alogliptin, Alogliptin
Class :
Anti-diabetics, Dipeptidyl Peptidase-IV Inhibitors
Brand Name :
Nesina,Incresync,kazano,oseni
Synonyms :
Alogliptin, Alogliptin
Class :
Anti-diabetics, Dipeptidyl Peptidase-IV Inhibitors
Dosage Forms & StrengthsÂ
TabletÂ
6.25mgÂ
12.5mgÂ
25mgÂ
25
mg
Tablet
Orally 
every day
Take one tablet orally twice daily with food
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
Dipeptidyl Peptidase-IV Inhibitors: they may increase the hypoglycemic effect of insulins
Dipeptidyl Peptidase-IV Inhibitors: they may increase the hypoglycemic effect of insulins
Dipeptidyl Peptidase-IV Inhibitors: they may increase the hypoglycemic effect of insulins
Dipeptidyl Peptidase-IV Inhibitors: they may increase the hypoglycemic effect of insulins
Dipeptidyl Peptidase-IV Inhibitors: they may increase the hypoglycemic effect of insulins
Dipeptidyl Peptidase-IV Inhibitors: they may increase the hypoglycemic effect of sulfonylureas
Dipeptidyl Peptidase-IV Inhibitors: they may increase the hypoglycemic effect of sulfonylureas
Dipeptidyl Peptidase-IV Inhibitors: they may increase the hypoglycemic effect of sulfonylureas
Dipeptidyl Peptidase-IV Inhibitors: they may increase the hypoglycemic effect of sulfonylureas
Dipeptidyl Peptidase-IV Inhibitors: they may increase the hypoglycemic effect of sulfonylureas
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
alogliptin: it may increase the risk of CNS depression
alogliptin: it may increase the risk of CNS depression
alogliptin: it may increase the risk of CNS depression
alogliptin: it may increase the risk of CNS depression
alogliptin: it may increase the risk of CNS depression
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may increase the hypoglycemic effect of Sulfonylureas
alogliptin: it may increase the risk of methemoglobinemia agents
alogliptin: it may increase the risk of methemoglobinemia agents
alogliptin: it may increase the risk of methemoglobinemia agents
alogliptin: it may increase the risk of methemoglobinemia agents
alogliptin: it may increase the risk of methemoglobinemia agents
may diminish the hypoglycemic effect
may increase the hypoglycemic effect of Antidiabetic Agents
Dipeptidyl Peptidase-IV Inhibitors: they may increase the toxic effect of angiotensin-converting enzyme inhibitors
Dipeptidyl Peptidase-IV Inhibitors: they may increase the toxic effect of angiotensin-converting enzyme inhibitors
Dipeptidyl Peptidase-IV Inhibitors: they may increase the toxic effect of angiotensin-converting enzyme inhibitors
Dipeptidyl Peptidase-IV Inhibitors: they may increase the toxic effect of angiotensin-converting enzyme inhibitors
Dipeptidyl Peptidase-IV Inhibitors: they may increase the toxic effect of angiotensin-converting enzyme inhibitors
When medrysone is used in conjunction with alogliptin, the risk or seriousness of hyperglycemia can rise
When used with levobetaxolol, alogliptin's therapeutic effectiveness may be enhanced
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
tinidazole has the potential to reduce the rate of excretion of alogliptin, potentially leading to an elevation in level of serum
When alogliptin is used together with promazine, this leads to a reduction in alogliptin metabolism
When alogliptin is used together with polythiazide, this leads to a reduction in the therapeutic effectiveness of alogliptin
alogliptin leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
cefpirome leads to a reduction in the rate of excretion of alogliptin which leads to increased level of serum
alogliptin leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
alogliptin leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
alogliptin leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
alogliptin: it may decrease the excretion rate of iothalamic acid
alogliptin: it may increase the risk of lidoflazine
proquazone may slow down the pace at which alogliptin is excreted, which could result in a rise in serum levels
clonixin may slow down the drug's elimination rate, which could result in elevated serum levels
tepoxalin may reduce the excretion rate of alogliptin, potentially leading to higher serum levels
niflumic acid may lower the excretion rate of alogliptin, which could result in a raised serum level
the efficacy of alogliptin can be raised when used in combination with sulfametopyrazine
alogliptin may diminish the excretion speed of hydroxyethyl starch, potentially leading to an elevated serum level
When helometasone is used together with alogliptin, this leads to elevated risk or seriousness of hyperglycemia
When alogliptin is used together with diazoxide, this leads to reduction in therapeutic effectiveness of alogliptin
methylprednisolone hemisuccinateÂ
When methylprednisolone hemisuccinate is aided with alogliptin, this leads to elevated hyperglycemia risk
when both drugs are combined, there may be a decreased therapeutic efficacy of alogliptin  
may increase the hypoglycemic effect
choline magnesium trisalicylate
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
the rate of excretion of alogliptin may be reduced
flunixin may lower the excretion rate of alogliptin which could result in a raised serum level
the risk of hyperglycemia may be increased
the therapeutic activity of alogliptin may be increased
When alogliptin is used together with oliceridine, this leads to reduction in oliceridine’s metabolism
etoricoxib: it may decrease the excretion rate of alogliptin
alogliptin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
the hypoglycemic effect of alogliptin may be enhanced
dipeptidyl peptidase-IV inhibitors increase the effect of hypoglycemia of sulfonylureas
dipeptidyl peptidase-IV inhibitors increase the effect of hypoglycemia of sulfonylureas
dipeptidyl peptidase-IV inhibitors increase the effect of hypoglycemia of sulfonylureas
dipeptidyl peptidase-IV inhibitors increase the effect of hypoglycemia of sulfonylureas
dipeptidyl peptidase-IV inhibitors increase the effect of hypoglycemia of sulfonylureas
dipeptidyl peptidase-IV inhibitors increase the effect of hypoglycemia of insulins
dipeptidyl peptidase-IV inhibitors increase the effect of hypoglycemia of insulins
dipeptidyl peptidase-IV inhibitors increase the effect of hypoglycemia of insulins
dipeptidyl peptidase-IV inhibitors increase the effect of hypoglycemia of insulins
dipeptidyl peptidase-IV inhibitors increase the effect of hypoglycemia of insulins
Frequency defined:Â Â
>10%Â
HypoglycemiaÂ
1-10%Â
HeadacheÂ
NasopharyngitisÂ
Upper respiratory tract infectionsÂ
<1%Â
PancreatitisÂ
HypersensitivityÂ
Post-marketing reportsÂ
IleusÂ
DiarrheaÂ
RhabdomyolysisÂ
Hepatic failureÂ
Stevens-Johnson syndromeÂ
ArthralgiaÂ
Tubulointerstitial nephritisÂ
NauseaÂ
AngioedemaÂ
UrticariaÂ
Pregnancy consideration: BÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: alogliptinÂ
Pronounced: AL-oh-GLIP-tinÂ
Why do we use alogliptin?Â
It is used to treat hyperglycemia (High sugar levels) in patients suffering from type 2 diabetes mellitusÂ
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
